• Profile
Close

Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma

Lung Cancer Dec 02, 2020

Ghirardelli P, Franceschini D, D’Aveni A, et al. - Researchers conducted this retrospective analysis to determine the role of focal radiotherapy (FRT) as a therapeutic choice for oligo-progressive malignant pleural mesothelioma (MPM). This study involved consecutive patients pretreated with ≥ 1 lines of chemotherapy. Either stereotactic body radiotherapy (SBRT, ≥ 5 Gy per fraction) or hypo-fractionated radiotherapy (hypoRT, < 5 Gy per fraction) was administered to patients. The primary endpoints included time to further systemic therapy (TFST) and local control (LC) following FRT. The median TFST was estimated to be 6 months. At 6 months and 1 year, LC was 84% and 76%, respectively. Overall, findings revealed that in selected patients with oligo-progressive MPM, it was feasible to use FRT as a treatment option, which not only permitted delay of further systemic therapies but also did not result in severe toxicity. Results demonstrated greater effectiveness of FRT when performed at progression following one line of systemic therapy. A radio-resistant behavior of MPM was indicated.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay